PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Complete if Known				
Application Number	10/810,165			
Filing Date	03/26/2004			
First Named Inventor	David S. F. Young			
Art Unit	1642			
Examiner Name				
Attorney Docket Number	2056.040	フ		

U. S. PATENT DOCUMENTS Name of Patentee or Pages Columns Lines Where Examiner Document Number Publication Date MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code<sup>2 (d known)</sup> US- 4,861,581 LAR 08/29/1989 Epstein et al <sup>US-</sup> 5,171,665 Hellstrom et al 12/15/1992 US- 5,484,596 01/16/1996 Hanna, Jr., et al 12/02/1997 US- 5,693,763 Codington et al <sup>US-</sup> 5,750,102 05/12/1998 Eisenbach et al US- 5,780,033 07/14/1998 Torchilin et al US- 5,783,186 07/21/1998 Arakawa et al US- 5,849,876 12/15/1998 Linsley et al US- 5,869,045 Hellstrom et al 02/09/1999 <sup>US-</sup> 5,869,268 02/09/1999 Kudo et al <sup>US-</sup> 5,916,561 Adolf et al 06/29/1999 <sup>US-</sup> 5,616,468 Salmi et al 04/01/1997 US-5,879,898 03/09/1999 Tarin et al US- 5,942,417 08/24/1999 Ni et al US- 5,885,575 Herrlich et al 03/23/1999 US- 6,180,357 01/30/2001 Young et al Young et al US- 6,657,048 12/02/2003 US- 2003/0103985 06/05/2003 Adolf et al US- 2004/0105815 06/03/2004 Young et al

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
LAB		WO02/094879	11/28/2002	Boehringer Ingelheim Int'i GMBH et al		
					•	
				<u> </u>		L
					-	┡
	ļ					<b> -</b> -
	1				L	L

Examiner Signature Date Considered 4/19/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copylof this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 'Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sheet

Attorney Docket Number | 2056.040

				T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (d known)</sup>	<del></del>	<del> </del>	1.9-1-0-1-1-1-1
رممر		<sup>US-</sup> 2005/0008646	01/13/2005	Young et al	
		US-			-
		US-			
_		US-			
	<u> </u>	US-			· <del> </del>
		US-			
,		US-	<del></del>		
		US-			<del>                                     </del>
		U\$-			· · · · · · · · · · · · · · · · · · ·
		US-			
	-	US-			
		US-			<del></del>
<del></del>	<del>                                     </del>	US-	<del></del>		

	FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
- <del></del>		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°			
		7-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2							
						<u> </u>			
						▙			
						⊬			
						<u>L</u>			
	l			ľ		ŀ			

			_		1						
Examiner Signature	SK.	ym	$\mathcal{E}$	Fan	K	<u>'</u>	Date Considered	4/	19/	106	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not inconformance and not considered. Include copy of his form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
b a collection of information unless it contains a valid OMB control number.

Noder the Paperwork Reduction Act of 1995, no persons are	U.S. Patent a e required to respond to a collection of	nd I Facernia Number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number.  Complete if Known
Substitute for form 1449/PTO	Application Number	10/810,165
	Filing Date	03/26/2004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	David S. F. Young
STATEMENT BY ALL LIST	Art Unit	1642
(Use as many sheets as necessary)	Examiner Name	
6	Attorney Docket Number	2056.040
Sheet 3 of 0		

xaminer	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, sy	T <sup>2</sup>
nitials*	No.1	Number(9); per adherion malecule inhibits drug-induced apoptosis in numari	
LAB		myeloid leukemia ceiis , dioda otto	
1		BARSHACK et al, CD44 expression in normal adrenal tissue and adrenal tumors", J. Clin. Pathol., 51:52-54	
		(1998)  R. BREYER et al, "Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-	
		CD44 monocional antibody ; over the control of the	
		allows dose escalation of the Concer Res. 8:3401-3406 (November, 2002)	
	-	dose escalation study", Clin. Cancer Nool, etc.  D. COLNOT et al, "Radioimmunotherapy in patients with head and neck squamous cells carcinoma:initial experience", Head & Neck, 23:559-565 (July, 2001)	
	-	D. COLNOT et al, "Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck", J. Nucl. Med., 41:1999-2010 (December, 2000)	
	+-	D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to product the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy", J. Nucl. Med., 42	
+		(9):1364-1367 (September, eco.)  A. DAAR et al, "The membrane antigens of human colorectal cancer cells:demonstration with monoconal action of the september of	-
-	-	R. DE BREE et al, "Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvent teaching and neck cancer patients", British J. Cancer, 75(7):1049-1060 (1997)	
-	-	R. DE BREE et al, "Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer", Clin. Can. Res., 1:591-598 (June, 1995)	

$\mathcal{L}$			,
	<u> </u>	Date	14/19/10h
Everniner	(M. 5 (M)	Considered	1 1/1 1/20 _
Examiner	Our Control Considered, whether or not citation is in conformance with MPEP	609. Draw line through o	itation if not in conformance and not
Signature	considered, whether or not citation is in conformance with wire cr	000. 2.2.	- tri is stacked

<sup>\*</sup>EXAMINER: Initial if refere the considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of Information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including antiportion of the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the gathering upon the individual case. Any comments on the gathering upon the individual case. Any comments of the gathering upon the individual case. Any comments of the gathering upon the individual case. Any comments of the gathering upon the individual case. Any comments of the gathering upon the i Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

as collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no perso	ns are required to respond to a collection	of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid OMB control number of information unless it contains a valid of information unless it contains a val
Substitute for form 1449/PTO	Application Number	10/810,165
	Filing Date	03/26/2004
INFORMATION DISCLOSUR	\L-	David S. F. Young
STATEMENT BY APPLICAN	Art Unit	1642
(Use as many sheets as necessary)	Examiner Name	
	Attorney Docket Number	2056.040
Sheet 4 of 6		

	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), date, pa	T <sup>2</sup>		
xaminer nitials*	No.1	The state of the s			
. ,\0		number(s), publisher, city and/or county where passesses number(s), publisher, city and/or county where passesses number(s), publisher, city and/or county where passesses numbers against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation", J. Immunol., 144:7-15 (January, 1990)			
LAB		B. FLANAGAN et al, "Chemical composition and tissue distribution of the human CDw44 glycoprotein", Immunol., 67:167-175 (1989)			
	<u> </u>	The most burnan tissues, in addition to some tumors, express multiple different CD44 isoforms",			
		Cancer Res., 54:4539-4546 (163-4)			
	+	U. GUNTHERT et al. "A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells", Cell, 65:13-24 (April, 1991)	_		
	<del> </del>	Y. GUO et al, "Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibod Cancer Res., 54:1561-1565 (March, 1994)	y".		
	-	K. HEIDER et al, "Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa", Cancer Res., 53:4197-4203 (September, 1993)			
		K. HEIDER et al, "A human homologue of the rat metastasis-associated variant of CD44 is expressed in calculated carcinomas and adenomatous polyps", J. Cell Biol., 120:27-233 (January, 1993)			
	K. HEIDER et al. "Splice variants of the cell surface glycoprotein CD44 associated with metastatic are expressed in normal tissues of humans and cynomolgus monkeys", Eur. J. Cancer, 31A(13/14)		<del> </del>		
	-	(1995)  K. HEIDER et al, "Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate immunotherapy of squamous cell carcinomas", Cancer Immunol. Immunother., 43:245-253 (1996)	ior		
S. JALKANEN et al, "Biochemical properties of glycoproteins involved in lymphocyte recognition of endothelial venules in man", J. Immunol., 141:1615-1623 (September, 1988)					

	3.0	Date	4/19/14
Examiner	Mand whether or not citation is in conformance	Considered	itation if not in conformance and not
Signature	whether or not citation is in conformance	with MPEP 609. Draw line though	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete on process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete on process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete on process. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the complete day of the process of the complete day of the process of

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

		uction Ac	or 1995, 10 persons en	Complete if Known		
Substitute	for form 1449/PTO			Application Number	10/810,165	
INFO	RMATION	I DIS	CLOSURE	Filing Date	03/26/2004	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	David S. F. Young	
				Art Unit	1642	
				Examiner Name		
Sheet	5	of	6	Attorney Docket Number	2056.040	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
21 <u>08</u>		S. KAYASTHA et al, "Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival", Clin. Cancer Res., 5:1073-1076 (May, 1999)	
		S. KENNEL et al, "CD44 expression on murine tissues", J. Cell Science, 104:373-382 (1993)	
		M. KHOURSHEED et al, "Expression of CD44s in human colorectal cancer", Pathology Oncology Research, 8 (3):170-174 (2002)	
		G. KOOPMAN et al, "Activated human lymphocytes and aggressive non-hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44", J. Exp. Med., 177:897-904 (April, 1993)	
		M. KUPPNER et al, "Differential expression of the CD44 molecule in human brain tumours", Int. J. Cancer, 50:572-577 (1992)	
		C. MACKAY et al, "Expression and modulaton of CD44 variant isoforms in humans", J. Cell Biol., 124:71-82 (January, 1994)	
		D. NAOR et al, "CD44 in cancer", Critical Reviews in Clinical Laboratory Science, 39(6):527-579 (2002)	
	-	H. PONTA et al, "CD44: from adhesion molecules to signaling regulators", Nature Reviews, Molecular Cell Biology, 4:33-45 (January, 2003)	
		J. ROSS et al, "Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma", Mod. Pathol., 9(8):854-860 (1996)	
		M. SAMI et al, "Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin", J. Cell Biol., 122(2):431-442 (July, 1993)	

Examiner Signature	Shan Famulo	Date Considered	4/19/06
-53.00 I	itial if reference considered, whether or not citation is in confor	mance with MPEP 609. Draw line through c	itation if not in conformance and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of collection of information unless it contains a valid OMB control number.

plete if Known	Under the Paperwork Reduction Act of 1995, no persons are						
310,165	Application Number	Substitute for form 1449/PTO					
26/2004	Filing Date	INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
vid S. F. Young	First Named Inventor						
12	Art Unit				יאוט		
	Examiner Name	(Use as many sheets as necessary)					
56.040	Attorney Docket Number	6	of	6	Sheet		
	Examiner Name	ecessary)	(Use as many sheets as necessary)				

xaminer	Cite No.1	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAB		A. SCHRIJVERS et al, "MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck", Cancer Res., 53:4383-4390 (September, 1993)	
		S. SEITER et al, "Prevention of tumor metastasis formation by anti-variant CD44", J. Exp. Med., 177:443-455 (February, 1993)	
		Y. SHIMIZU et al, "Dual role of the CD44 molecule in T cell adhesion and activation", J. Immunol., 143:2457-2463 (October, 1989)	
		T. STROBEL et al, "In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation", Cancer Res., 57:1228-1232 (April, 1997)	
		J. STROOMER et al, "Safety and biodistribution of 99m Technetium-labeled anti-CD44v6 monoclonal antiody BIWA 1 in head and neck cancer patients", Clin. Can. Res., 6:3046-3055 (August, 2000)	
	-	N. VAN HAL et al, "Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform", Int. J. Cancer, 68:520-527 (1996)	
	-	S. WALLACH-DAYAN et al, "CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes", J. Cell Science, 114:3463-3477 (2001)	
		M. ZAHALKA et al, "Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent", J. Immunol., 154:5345-5355 (1995)	
	-	V. ZAWADZKI et al, "blockade of metastasis formation by CD44-receptor globulin", Int. J. Cancer, 75:919-924 (1998)	
-			

	<u> </u>		
		Date	1 11 1
Examiner		1 -	17/19/16
	James Month	Considered	1/11/00
Signature	and whether or not citation is in conformance with MPEP 6	on Described through o	tation if not in conformance and not
0.5	the distriction is in conformance with MPEP 6	09. DISM little it it ood it it	Aldudit ii fiot iii comme

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

1 Applicant's unique citation designation is attached.

2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

2 Applicant is to place a check mark here if English language Translation is attached.

3 Applicant is unique citation is attached.

3 Applicant is to place a check mark here if English language Translation is attached.

4 Applicant's unique citation is attached.

5 Initiation is negative in exclusion is attached.

5 Initiatian a benefit by the public which is to file (and by the USPTO This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application.

5 Confidential Translation is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection is attached.

6 Applicant is unique citation to retain a benefit by the public which is to file (and by the USPTO This collection is attached.

6 Applicant is to process an

Inder the Partier Reduction
Substitute for form 1449/PTO

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Application Number** 10/810,165 03/26/2004 Filing Date David S. F. Young First Named Inventor 1642 Art Unit **Examiner Name** 

(Use as many sheets as necessary) 2056.040 Attorney Docket Number Sheet

			U. S. PATENT	DOCUMENTS	Pages, Columns, Lines, Where
xaminer	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (if known)</sup>		D. Voung et al	1
LAB		<sup>US-</sup> 2004/0001789A1	01/01/2004	D. Young et al	
		US-			
	1	US			
		US-		<u> </u>	
		US-			
		US-			
	1	U\$-			
		US-			
	+-	US-	1		

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Τ <sup>6</sup>
LAB		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (# known) WO2003/055515	07/10/2003	Arius Research Inc		

i i			
		Date Considered	4/19/11
Examiner	()	Considered	1/17/06
Signature	aym Made	w line through	citation if not in conformance and no

Signature Considered 1/1706

EXAMINER: Initial if Jeference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant, applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant, applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant, applicant is two-letter code (WIPO Standard ST.3). For USFTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. The indication of the year of the reign of the Emperor must precede the serial number of the patent document. The patent document is appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspections from the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Unde	er the Paperwork Redu	uction Act	of 1995, no persons an	required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Substitute	for form 1449/PTO			Application Number	10/810,165	
INIEC	OMATION	DIS	CLOSURE	Filing Date	03/26/2004	
INFC	TEMENT E	BY A	PPLICANT	First Named Inventor	David S. F. Young	
JIA				Art Unit	1642	
	(Use as many she	ets as m	ecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	2056.040	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAB		D. YOUNG et al, "ARH460-16-2: A therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer", Journal of Clinical Oncology, 22:193s (July, 2004) Abstract 2622	
	-		
	+-		

Examiner	(); E &	Date Considered	4/19/06
Signature	The state of the s		itation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation if not in conformance and not considered.

2 Applicant is to place a check mark here if English language Translation is attached.

3 Applicant is to place a check mark here if English language Translation is attached.

4 Applicant's unique citation if not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

4 Applicant's unique citation if not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

5 Applicant is to place a check mark here if English language Translation is attached.

6 Applicant is unique citation is attached.

6 Applicant is to place a check mark here if English language Translation is attached.

7 Applicant is to place a check mark here if English language Translation is attached.

7 Applicant is to place a check mark here if English language Translation is attached.

8